| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $3,807,597 | 26 | 100 |
| Sanders Corazon (Corsee) D. | director | 0 | $0 | 1 | $50,100 | $-50,100 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 0 | $0 | 3 | $57,542 | $-57,542 |
| SULIMAN SHEHNAAZ | director | 0 | $0 | 1 | $144,189 | $-144,189 |
| Crombez Eric | EVP and Chief Medical Officer | 0 | $0 | 2 | $168,847 | $-168,847 |
| Pinion John Richard | See Remarks | 0 | $0 | 1 | $228,661 | $-228,661 |
| Harris Erik | EVP & Chief Commercial Officer | 0 | $0 | 1 | $240,289 | $-240,289 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 0 | $0 | 5 | $487,891 | $-487,891 |
| Horn Howard | Chief Financial Officer | 0 | $0 | 11 | $1.19M | $-1.19M |
| KAKKIS EMIL D | President & CEO | 0 | $0 | 1 | $1.24M | $-1.24M |
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement …
Over the last 12 months, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $3.81M worth of Ultragenyx Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $5.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $218,150 was made by KAKKIS EMIL D (President & CEO) on 2019‑09‑11.
| 2026-10-15 | Sale | Horn Howard | Chief Financial Officer | 7,066 0.0072% | $15.27 | $107,898 | +6.00% | |
| 2026-09-15 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 1,283 0.0014% | $13.57 | $17,410 | +16.07% | |
| 2026-08-03 | Sale | Horn Howard | Chief Financial Officer | 4,696 0.0046% | $24.92 | $117,024 | -37.45% | |
| 2026-08-03 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 1,900 0.0019% | $24.92 | $47,348 | -37.45% | |
| 2026-07-01 | Sale | Horn Howard | Chief Financial Officer | 4,698 0.0049% | $33.13 | $155,645 | -23.07% | |
| 2026-06-15 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 1,899 0.0019% | $24.62 | $46,753 | -0.45% | |
| 2026-06-15 | Sale | Sanders Corazon (Corsee) D. | director | 2,000 0.0021% | $25.05 | $50,100 | -0.45% | |
| 2026-06-01 | Sale | Horn Howard | Chief Financial Officer | 4,653 0.0047% | $23.77 | $110,602 | +9.06% | |
| 2026-05-18 | Sale | SULIMAN SHEHNAAZ | director | 5,740 0.0059% | $25.12 | $144,189 | -1.03% | |
| 2026-05-05 | Sale | Crombez Eric | EVP and Chief Medical Officer | 344 0.0003% | $24.96 | $8,586 | -0.52% | |
| 2026-05-01 | Sale | Horn Howard | Chief Financial Officer | 4,683 0.0048% | $24.90 | $116,607 | +0.44% | |
| 2026-04-01 | Sale | Horn Howard | Chief Financial Officer | 4,683 0.0047% | $20.97 | $98,203 | +14.47% | |
| 2026-03-10 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 3,508 0.0036% | $22.67 | $79,526 | +4.99% | |
| 2026-03-06 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 6,018 0.0063% | $21.40 | $128,785 | +12.66% | |
| 2026-03-03 | Sale | Horn Howard | Chief Financial Officer | 1,635 0.0016% | $22.40 | $36,624 | +7.88% | |
| 2026-03-02 | Sale | KAKKIS EMIL D | President & CEO | 54,404 0.0549% | $22.80 | $1.24M | +3.00% | |
| 2026-03-02 | Sale | Pinion John Richard | See Remarks | 10,029 0.0101% | $22.80 | $228,661 | +3.00% | |
| 2026-03-02 | Sale | Harris Erik | EVP & Chief Commercial Officer | 10,539 0.0106% | $22.80 | $240,289 | +3.00% | |
| 2026-03-02 | Sale | Horn Howard | Chief Financial Officer | 8,409 0.0084% | $22.70 | $190,914 | +3.00% | |
| 2026-03-02 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 8,135 0.0082% | $22.80 | $185,478 | +3.00% |
| KAKKIS EMIL D | President & CEO | 658994 0.6684% | $10.96M | 2 | 28 | +13.31% |
| FMR LLC | 10 percent owner | 3260240 3.3069% | $54.22M | 1 | 0 | +10.41% |
| Kassberg Thomas Richard | CBO & EVP | 265238 0.269% | $4.41M | 1 | 26 | +10.12% |
| Sharp Shalini | EVP, Finance | 97812 0.0992% | $1.63M | 1 | 28 | +10.12% |
| Aliski William | director | 65704 0.0666% | $1.09M | 1 | 13 | +10.12% |
| Fust Matthew K | director | 14860 0.0151% | $247,121.80 | 1 | 6 | +10.12% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B |
| Increased Positions | 171 | +49.14% | 18M | +18.8% |
| Decreased Positions | 160 | -45.98% | 19M | -20.22% |
| New Positions | 56 | New | 5M | New |
| Sold Out Positions | 66 | Sold Out | 7M | Sold Out |
| Total Postitions | 359 | +3.16% | 95M | -1.41% |
| Vanguard Group Inc | $239,132.00 | 10.56% | 10.13M | -80,694 | -0.79% | 2025-09-30 |
| Fmr Llc | $171,886.00 | 7.59% | 7.28M | +5M | +179.63% | 2025-09-30 |
| Blackrock, Inc. | $151,636.00 | 6.69% | 6.43M | +169,118 | +2.7% | 2025-09-30 |
| Jpmorgan Chase & Co | $94,670.00 | 4.18% | 4.01M | +750,561 | +23.02% | 2025-09-30 |
| Sands Capital Management, Llc | $88,969.00 | 3.93% | 3.77M | -173,632 | -4.4% | 2025-09-30 |
| State Street Corp | $87,143.00 | 3.85% | 3.69M | +1M | +43.55% | 2025-09-30 |
| Rtw Investments, Lp | $76,895.00 | 3.39% | 3.26M | +2M | +90.83% | 2025-09-30 |
| Baker Bros. Advisors Lp | $65,436.00 | 2.89% | 2.77M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $54,520.00 | 2.41% | 2.31M | -576,094 | -19.96% | 2025-09-30 |
| Jacobs Levy Equity Management, Inc | $51,158.00 | 2.26% | 2.17M | +2M | +614.09% | 2025-09-30 |